Bielefeld C, Hugo T, Sievers N, Ketteler P, Biewald E, Kiefer T, Papaioannou K, Tüller P, Ryl T, Busch M, Rawitzer J, Schildhaus H-U, Ting S
Reference Pathology for Pediatric Eye Tumors, Kassel, Germany.
Institute of Pathology Nordhessen, Germaniastrasse 7, 34119, Kassel, Germany.
Virchows Arch. 2025 Aug 21. doi: 10.1007/s00428-025-04219-x.
Retinoblastoma is a malignant childhood neoplasm where MYCN amplification defines a subset of tumors with worse prognosis. FISH (fluorescence in situ hybridization) represents a fast and reliable method to measure gene copy numbers in various tumors but has not yet been systematically evaluated in retinoblastoma. In this study, we define criteria for FISH detection of MYCN amplification in a systematic unbiased approach by using a well characterized series of 44 clinical retinoblastoma samples. We (i) determined potential measurements and parameters by a comprehensive literature review, (ii) analyzed a retrospective cohort of samples with known MYCN amplification, (iii) determined statistically measurements and cut-offs, which allow reliable detection of amplified tumors, and (iv) applied these criteria to a prospective cohort. We demonstrate that average gene copy number (AVGCN) of MYCN/cell, MYCN/CEN2 ratio, and MYCN-CEN2 difference reveal the lowest statistical variance in amplified samples, if at least 50 cells were counted. The combination of these three parameters and cut-offs, namely AVGCN ≥ 10, MYCN/CEN2 ratio ≥ 3, and MYCN-CEN2 difference ≥ 8, allowed a reliable distinction between amplified and non-amplified cases. The prevalence of MYCN-amplified cases was 4/33 (12.1%) among prospective clinical samples indicating a higher percentage of positive tumors than previously reported. Our data provide the first evidence for well-grounded MYCN FISH criteria in retinoblastoma.
视网膜母细胞瘤是一种儿童恶性肿瘤,其中MYCN基因扩增定义了一组预后较差的肿瘤。荧光原位杂交(FISH)是一种快速可靠的方法,可用于测量各种肿瘤中的基因拷贝数,但尚未在视网膜母细胞瘤中进行系统评估。在本研究中,我们通过使用44例具有明确特征的临床视网膜母细胞瘤样本,以系统无偏倚的方法定义了FISH检测MYCN基因扩增的标准。我们(i)通过全面的文献综述确定了潜在的测量方法和参数,(ii)分析了一组已知MYCN基因扩增的回顾性样本队列,(iii)确定了统计学测量方法和临界值,以实现对扩增肿瘤的可靠检测,(iv)将这些标准应用于前瞻性队列。我们证明,如果至少计数50个细胞,MYCN/细胞的平均基因拷贝数(AVGCN)、MYCN/CEN2比值和MYCN-CEN2差异在扩增样本中显示出最低的统计方差。这三个参数和临界值的组合,即AVGCN≥10、MYCN/CEN2比值≥3和MYCN-CEN2差异≥8,能够可靠地区分扩增和未扩增病例。在前瞻性临床样本中,MYCN扩增病例的患病率为4/33(12.1%),表明阳性肿瘤的比例高于先前报道。我们的数据为视网膜母细胞瘤中基于充分证据的MYCN FISH标准提供了首个证据。